한글목차

이 보고서는 다발성 경화증(MS) 시장을 조사했으며, 경구용 질환 조절 요법(DMT)의 쇠퇴와 보다 효과적인 치료법의 등장에 초점을 맞추어 다발성 경화증(MS) 치료의 현재와 미래를 종합적으로 분석합니다.

보고서에서 다룬 주요 브랜드

기업

목차

주요 요약

치료 알고리즘

조사 목적

• 출시 의약품
  • Oral disease-modifying therapies
  • Second-generation sphingosine modulators
  • Mavenclad (cladribine; Merck Group)
  • Tysabri (natalizumab; Biogen)
  • Anti-CD20 monoclonal antibodies
• 파이프라인 의약품
  • Masitinib(AB Science)
  • Tolebrutinib(Sanofi)
  • Fenebrutinib(Roche)
  • Remibrutinib(Novartis)
  • Vidofludimus calcium(IMU-838, Immunic)
  • Frexalimab(Sanofi/ImmuNext)
• MS에의 조기 단계 접근
  • 주요 견해 요약

부록

영문목차

This report provides a comprehensive analysis of the current and future landscape of multiple sclerosis (MS) therapies, focusing on the decline of oral disease-modifying therapies (DMTs) and the rise of higher-efficacy treatments. It examines the market dynamics of key therapies like Zeposia, Mavenclad, and Tysabri, and explores the potential of emerging treatments such as masitinib and tolebrutinib.

Key questions answered:

• 1. What events are impacting the uptake of oral DMTs?
• 2. How are therapies perceived by the medical community in terms of efficacy, tolerability, and ease of administration?
• 3. Which recently completed or ongoing clinical trials have the greatest potential to affect prescribing trends?
• 4. What will DMTs need to show to become the treatment of choice in specific therapy lines?
• 5. How will the use of each current and pipeline DMT change in the future in terms of line of therapy and preference?
• 6. What will pipeline products need to show in terms of efficacy and tolerability to compete with current therapies?
• 7. Which pipeline products are the most promising, and how will they impact current market players?
• 8. How will the treatment landscape for MS evolve in the future for each patient segment and line of therapy?

Key brands covered in this report:

Companies:

Table of Contents

Executive summary

Treatment algorithm

Research objectives

• Marketed drugs
  • Oral disease-modifying therapies
  • Second-generation sphingosine modulators
  • Mavenclad (cladribine; Merck Group)
  • Tysabri (natalizumab; Biogen)
  • Anti-CD20 monoclonal antibodies
• Pipeline drugs
  • Masitinib (AB Science)
  • Tolebrutinib (Sanofi)
  • Fenebrutinib (Roche)
  • Remibrutinib (Novartis)
  • Vidofludimus calcium (IMU-838; Immunic)
  • Frexalimab (Sanofi/ImmuNext)
• Earlier-stage approaches for MS
  • Key insights summary

Appendix

• KOL details
  • KOLs from North America
  • KOLs from Europe